When did apotex gain fda approval for ruxolitinib?

Apotex gained FDA approval for ruxolitinib on 6 July 2023.

How does the Apotex approval differ from the original Jakafi brand?
Apotex received approval for a generic version of ruxolitinib phosphate tablets in 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg strengths. The generic is therapeutically equivalent to Jakafi and can be substituted by pharmacists under state laws that permit generic interchange.

What prompted Apotex to file its abbreviated new drug application?
Apotex filed an ANDA after the original composition-of-matter patents on ruxolitinib expired, allowing generic entry once the FDA confirmed bioequivalence and manufacturing standards.

Why are some pharmacies still dispensing only the brand-name Jakafi?
Certain states require specific prescriber notation for substitution, and some insurance plans maintain higher copays for the generic until formulary updates are complete. In addition, Incyte’s authorized generic partner began shipping earlier, which can temporarily limit shelf space for other generics.

When did ruxolitinib first lose U.S. patent protection?
The key composition-of-matter patent (U.S. Patent No. 7,598,257) expired on 3 December 2022, opening the pathway for ANDA approvals like Apotex’s.

Can biosimilars or additional generics launch before full patent clearance?
No. Ruxolitinib is a small-molecule drug, so biosimilar rules do not apply. Any further generic entry depends on remaining regulatory exclusivities or ongoing litigation settlements.

Who manufactures the Apotex ruxolitinib tablets?
Apotex Corp., headquartered in Toronto, produces the finished tablets at its facilities in Canada and India, both inspected and approved by the FDA.

How much lower is the cost of Apotex ruxolitinib compared with Jakafi?
Wholesale acquisition cost for the Apotex generic is roughly 80–85 % below the brand price, though actual pharmacy and patient costs vary by insurance coverage and negotiated discounts.